{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:14:41Z","timestamp":1776323681455,"version":"3.50.1"},"posted":{"date-parts":[[2024,12,14]]},"group-title":"Genetic and Genomic Medicine","reference-count":91,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Recent advancements in Parkinson\u2019s disease (PD) drug development have been significantly driven by genetic research. Importantly, drugs supported by genetic evidence are more likely to be approved. While genome-wide association studies (GWAS) are a powerful tool to nominate genomic regions associated with certain traits or diseases, pinpointing the causal biologically relevant gene is often challenging. Our aim was to prioritize genes underlying PD GWAS signals.<\/jats:p>\n                <jats:p>The polygenic priority score (PoPS) is a similarity-based gene prioritization method that integrates genome-wide information from MAGMA gene-level association tests and more than 57,000 gene-level features, including gene expression, biological pathways, and protein-protein interactions. We applied PoPS to data from the largest published PD GWAS in East Asian- and European-ancestries.<\/jats:p>\n                <jats:p>\n                  We identified 120 independent associations with\n                  <jats:italic>P<\/jats:italic>\n                  &lt; 5\u00d710\n                  <jats:sup>\u22128<\/jats:sup>\n                  and prioritized 46 PD genes across these loci based on their PoPS scores, distance to the GWAS signal, and presence of non-synonymous variants in the credible set. Alongside well-established PD genes (\n                  <jats:italic>e.g., TMEM175<\/jats:italic>\n                  and\n                  <jats:italic>VPS13C<\/jats:italic>\n                  ), some of which are targeted in ongoing clinical trials (\n                  <jats:italic>i.e.<\/jats:italic>\n                  ,\n                  <jats:italic>SNCA<\/jats:italic>\n                  ,\n                  <jats:italic>LRRK2<\/jats:italic>\n                  , and\n                  <jats:italic>GBA1<\/jats:italic>\n                  ), we prioritized genes with a plausible mechanistic link to PD pathogenesis (\n                  <jats:italic>e.g., RIT2, BAG3<\/jats:italic>\n                  , and\n                  <jats:italic>SCARB2<\/jats:italic>\n                  ). Many of these genes hold potential for drug repurposing or novel therapeutic developments for PD (\n                  <jats:italic>i.e., FYN, DYRK1A, NOD2, CTSB, SV2C,<\/jats:italic>\n                  and\n                  <jats:italic>ITPKB<\/jats:italic>\n                  ). Additionally, we prioritized potentially druggable genes that are relatively unexplored in PD (\n                  <jats:italic>XPO1, PIK3CA, EP300, MAP4K4, CAMK2D, NCOR1,<\/jats:italic>\n                  and\n                  <jats:italic>WDR43<\/jats:italic>\n                  ).\n                <\/jats:p>\n                <jats:p>We prioritized a high-confidence list of genes with strong links to PD pathogenesis that may represent our next-best candidates for disease-modifying therapeutics. We hope our findings stimulate further investigations and preclinical work to facilitate PD drug development programs.<\/jats:p>","DOI":"10.1101\/2024.12.13.24318996","type":"posted-content","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T18:15:11Z","timestamp":1734200111000},"source":"Crossref","is-referenced-by-count":2,"title":["Prioritizing Parkinson\u2019s disease risk genes in genome-wide association loci"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7162-9821","authenticated-orcid":false,"given":"Lara M.","family":"Lange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina","family":"Cerquera-Cleves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijn","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Panagiotaropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnil","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-835X","authenticated-orcid":false,"given":"Stephan","family":"Ripke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Blauwendraat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4776-1723","authenticated-orcid":false,"given":"Karl","family":"Heilbron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024121623102800000_2024.12.13.24318996v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30295-3"},{"issue":"5","key":"2024121623102800000_2024.12.13.24318996v1.2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.26467","article-title":"Effect Modification between Genes and Environment and Parkinson\u2019s Disease Risk","volume":"92","year":"2022","journal-title":"Ann Neurol"},{"key":"2024121623102800000_2024.12.13.24318996v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2023.03.009"},{"issue":"3","key":"2024121623102800000_2024.12.13.24318996v1.4","doi-asserted-by":"crossref","first-page":"e00348","DOI":"10.1016\/j.neurot.2024.e00348","article-title":"Neuroscience fundamentals relevant to neuromodulation: Neurobiology of deep brain stimulation in Parkinson\u2019s disease","volume":"21","year":"2024","journal-title":"Neurotherapeutics"},{"key":"2024121623102800000_2024.12.13.24318996v1.5","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-239901"},{"key":"2024121623102800000_2024.12.13.24318996v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07316-0"},{"key":"2024121623102800000_2024.12.13.24318996v1.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008489"},{"issue":"8","key":"2024121623102800000_2024.12.13.24318996v1.8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/d41573-022-00120-3","article-title":"Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs","volume":"21","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"2024121623102800000_2024.12.13.24318996v1.9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/d41573-023-00158-x","article-title":"Genetic support for FDA-approved drugs over the past decade","volume":"22","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2024121623102800000_2024.12.13.24318996v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3314"},{"issue":"8","key":"2024121623102800000_2024.12.13.24318996v1.11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrd4692","article-title":"Genetic information adds supporting weight","volume":"14","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2024121623102800000_2024.12.13.24318996v1.12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ana.26905","article-title":"Towards a Global View of Parkinson\u2019s Disease Genetics","volume":"95","year":"2024","journal-title":"Ann Neurol"},{"key":"2024121623102800000_2024.12.13.24318996v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30320-5"},{"key":"2024121623102800000_2024.12.13.24318996v1.14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26153"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.15","first-page":"226","article-title":"Genome-wide association study of Parkinson\u2019s disease in East Asians","volume":"26","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2024121623102800000_2024.12.13.24318996v1.16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","article-title":"Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study","volume":"77","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024121623102800000_2024.12.13.24318996v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00283-1"},{"key":"2024121623102800000_2024.12.13.24318996v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01584-8"},{"key":"2024121623102800000_2024.12.13.24318996v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01443-6"},{"key":"2024121623102800000_2024.12.13.24318996v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/S41588-021-00945-5"},{"issue":"3","key":"2024121623102800000_2024.12.13.24318996v1.21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awad345","article-title":"Machine learning nominates the inositol pathway and novel genes in Parkinson\u2019s disease","volume":"147","year":"2024","journal-title":"Brain"},{"key":"2024121623102800000_2024.12.13.24318996v1.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004219"},{"key":"2024121623102800000_2024.12.13.24318996v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq340"},{"key":"2024121623102800000_2024.12.13.24318996v1.24","doi-asserted-by":"crossref","unstructured":"Chang CC , Chow CC , Tellier LC , Vattikuti S , Purcell SM , Lee JJ . Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.","DOI":"10.1186\/s13742-015-0047-8"},{"key":"2024121623102800000_2024.12.13.24318996v1.25","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2213"},{"key":"2024121623102800000_2024.12.13.24318996v1.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004383"},{"key":"2024121623102800000_2024.12.13.24318996v1.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008720"},{"key":"2024121623102800000_2024.12.13.24318996v1.28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky955"},{"key":"2024121623102800000_2024.12.13.24318996v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00735-5"},{"key":"2024121623102800000_2024.12.13.24318996v1.30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw1055"},{"issue":"8","key":"2024121623102800000_2024.12.13.24318996v1.31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","article-title":"Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"22","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"2024121623102800000_2024.12.13.24318996v1.32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/mds.29346","article-title":"A Phase 1B Trial in GBA1-Associated Parkinson\u2019s Disease of BIA-28-6156, a Glucocerebrosidase Activator","volume":"38","year":"2023","journal-title":"Mov Disord"},{"key":"2024121623102800000_2024.12.13.24318996v1.33","doi-asserted-by":"crossref","unstructured":"Pagano G , Boess FG , Taylor KI , et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson\u2019s Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021;12:705407.","DOI":"10.3389\/fneur.2021.705407"},{"key":"2024121623102800000_2024.12.13.24318996v1.34","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27738"},{"key":"2024121623102800000_2024.12.13.24318996v1.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203395"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.36","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease","volume":"8","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"2024121623102800000_2024.12.13.24318996v1.37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial","volume":"77","year":"2020","journal-title":"JAMA Neurol"},{"issue":"19","key":"2024121623102800000_2024.12.13.24318996v1.38","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1093\/hmg\/ddz136","article-title":"Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease","volume":"28","year":"2019","journal-title":"Hum Mol Genet"},{"key":"2024121623102800000_2024.12.13.24318996v1.39","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy279"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41531-023-00484-2","article-title":"The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology","volume":"9","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41531-024-00648-8","article-title":"Silencing Parkinson\u2019s risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability","volume":"10","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"2024121623102800000_2024.12.13.24318996v1.42","doi-asserted-by":"crossref","unstructured":"Olsen AL , Feany MB . Parkinson\u2019s disease risk genes act in glia to control neuronal \u03b1-synuclein toxicity. Neurobiol Dis. 2021;159:105482.","DOI":"10.1016\/j.nbd.2021.105482"},{"key":"2024121623102800000_2024.12.13.24318996v1.43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi8287"},{"key":"2024121623102800000_2024.12.13.24318996v1.44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22169098"},{"key":"2024121623102800000_2024.12.13.24318996v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.09.010"},{"key":"2024121623102800000_2024.12.13.24318996v1.46","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M606147200"},{"issue":"4","key":"2024121623102800000_2024.12.13.24318996v1.47","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jnc.13164","article-title":"Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity","volume":"134","year":"2015","journal-title":"J Neurochem"},{"key":"2024121623102800000_2024.12.13.24318996v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2017.08.023"},{"key":"2024121623102800000_2024.12.13.24318996v1.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2011.01198.x"},{"key":"2024121623102800000_2024.12.13.24318996v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.05.006"},{"key":"2024121623102800000_2024.12.13.24318996v1.51","doi-asserted-by":"crossref","unstructured":"Lu SZ , Guo YS , Liang PZ , et al. Suppression of astrocytic autophagy by \u03b1B-crystallin contributes to \u03b1-synuclein inclusion formation. Transl Neurodegener. 2019;8:3.","DOI":"10.1186\/s40035-018-0143-7"},{"issue":"22","key":"2024121623102800000_2024.12.13.24318996v1.52","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.21037\/atm-22-5159","article-title":"BAG3 promotes autophagy and suppresses NLRP3 inflammasome activation in Parkinson\u2019s disease","volume":"10","year":"2022","journal-title":"Ann Transl Med"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s42003-020-0804-9","article-title":"Transcriptomic signatures of brain regional vulnerability to Parkinson\u2019s disease","volume":"3","year":"2020","journal-title":"Commun Biol"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13041-020-00712-3","article-title":"Fibroblasts from idiopathic Parkinson\u2019s disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2","volume":"14","year":"2021","journal-title":"Mol Brain"},{"key":"2024121623102800000_2024.12.13.24318996v1.55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neulet.2019.05.034","article-title":"Glucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain","volume":"706","year":"2019","journal-title":"Neurosci Lett"},{"key":"2024121623102800000_2024.12.13.24318996v1.56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1514005113"},{"key":"2024121623102800000_2024.12.13.24318996v1.57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","article-title":"Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells","volume":"82","year":"2015","journal-title":"Neurobiol Dis"},{"key":"2024121623102800000_2024.12.13.24318996v1.58","doi-asserted-by":"crossref","first-page":"129674","DOI":"10.1016\/j.bmcl.2024.129674","article-title":"Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights","volume":"102","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-023-03930-0","article-title":"FYN: emerging biological roles and potential therapeutic targets in cancer","volume":"21","year":"2023","journal-title":"J Transl Med"},{"key":"2024121623102800000_2024.12.13.24318996v1.60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084565"},{"key":"2024121623102800000_2024.12.13.24318996v1.61","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0119-0"},{"issue":"10","key":"2024121623102800000_2024.12.13.24318996v1.62","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial","volume":"76","year":"2019","journal-title":"JAMA Neurol"},{"key":"2024121623102800000_2024.12.13.24318996v1.63","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0302-15.2015"},{"key":"2024121623102800000_2024.12.13.24318996v1.64","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182191"},{"issue":"2","key":"2024121623102800000_2024.12.13.24318996v1.65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bpa.12917","article-title":"Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer\u2019s disease and Lewy body dementias","volume":"31","year":"2021","journal-title":"Brain Pathol"},{"key":"2024121623102800000_2024.12.13.24318996v1.66","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-017-0748-3"},{"key":"2024121623102800000_2024.12.13.24318996v1.67","doi-asserted-by":"crossref","unstructured":"Saminathan H , Charli A , Luo J , et al. Fyn kinase mediates pro-inflammatory response in a mouse model of endotoxemia: Relevance to translational research. Eur J Pharmacol. 2020;881:173259.","DOI":"10.1016\/j.ejphar.2020.173259"},{"key":"2024121623102800000_2024.12.13.24318996v1.68","doi-asserted-by":"crossref","unstructured":"Saminathan H , Ghosh A , Zhang D , et al. Fyn Kinase-Mediated PKC\u03b4 Y311 Phosphorylation Induces Dopaminergic Degeneration in Cell Culture and Animal Models: Implications for the Identification of a New Pharmacological Target for Parkinson\u2019s Disease. Front Pharmacol. 2021;12:631375.","DOI":"10.3389\/fphar.2021.631375"},{"key":"2024121623102800000_2024.12.13.24318996v1.69","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejmech.2018.08.093","article-title":"DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective","volume":"158","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"11","key":"2024121623102800000_2024.12.13.24318996v1.70","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/13543776.2017.1360285","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature","volume":"27","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"2024121623102800000_2024.12.13.24318996v1.71","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8100187"},{"key":"2024121623102800000_2024.12.13.24318996v1.72","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00185"},{"key":"2024121623102800000_2024.12.13.24318996v1.73","first-page":"8848642","article-title":"Dyrk1a phosphorylation of \u03b1-synuclein mediating apoptosis of dopaminergic neurons in Parkinson\u2019s disease","volume":"2023","year":"2023","journal-title":"Parkinsons Dis"},{"key":"2024121623102800000_2024.12.13.24318996v1.74","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3979098\/v1"},{"key":"2024121623102800000_2024.12.13.24318996v1.75","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddac047"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40035-023-00363-z","article-title":"Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models","volume":"12","year":"2023","journal-title":"Transl Neurodegener"},{"key":"2024121623102800000_2024.12.13.24318996v1.77","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00213-x"},{"key":"2024121623102800000_2024.12.13.24318996v1.78","doi-asserted-by":"publisher","DOI":"10.2165\/11204910-000000000-00000"},{"key":"2024121623102800000_2024.12.13.24318996v1.79","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1289-z"},{"key":"2024121623102800000_2024.12.13.24318996v1.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2010.09.063"},{"issue":"10","key":"2024121623102800000_2024.12.13.24318996v1.81","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/ejn.16311","article-title":"Synaptic vesicle glycoprotein 2C enhances vesicular storage of dopamine and counters dopaminergic toxicity","volume":"59","year":"2024","journal-title":"Eur J Neurosci"},{"key":"2024121623102800000_2024.12.13.24318996v1.82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616892114"},{"key":"2024121623102800000_2024.12.13.24318996v1.83","doi-asserted-by":"crossref","unstructured":"Kovacs G , Reimer L , Jensen PH . Endoplasmic Reticulum-Based Calcium Dysfunctions in Synucleinopathies. Front Neurol. 2021;12:742625.","DOI":"10.3389\/fneur.2021.742625"},{"key":"2024121623102800000_2024.12.13.24318996v1.84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031984"},{"key":"2024121623102800000_2024.12.13.24318996v1.85","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2006476118"},{"key":"2024121623102800000_2024.12.13.24318996v1.86","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00442-4"},{"key":"2024121623102800000_2024.12.13.24318996v1.87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904"},{"issue":"11","key":"2024121623102800000_2024.12.13.24318996v1.88","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/mds.28197","article-title":"The Parkinson\u2019s Disease Genome-Wide Association Study Locus Browser","volume":"35","year":"2020","journal-title":"Mov Disord"},{"issue":"1","key":"2024121623102800000_2024.12.13.24318996v1.89","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajhg.2023.12.006","article-title":"omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases","volume":"111","year":"2024","journal-title":"Am J Hum Genet"},{"key":"2024121623102800000_2024.12.13.24318996v1.90","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3955"},{"key":"2024121623102800000_2024.12.13.24318996v1.91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1166"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.12.13.24318996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:22:59Z","timestamp":1768508579000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.12.13.24318996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":91,"URL":"https:\/\/doi.org\/10.1101\/2024.12.13.24318996","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41531-025-00933-0","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,12,14]]},"subtype":"preprint"}}